Stem-cell therapy

Leading Stem Cell Clinic in the US Develops First Real "Stem Cell Face Mask"

Retrieved on: 
Tuesday, December 6, 2022
B cell, Peptide, Stem-cell therapy, Timeline of the COVID-19 pandemic, MSC, Neck pain, Arthralgia, Nerve injury, Psoriasis, Stem cell, Skin, Dementia, Health, Patient, COVID, Vampire, MS, Hyaluronic acid, Alzheimer's disease, Back pain, Medicine, Spring, Spinal cord injury, Quality of life, COVID 19, Acne, Osteoarthritis, Degenerative disease, Exosome, Crohn's disease, IV, COVID-19, Rejuvenation, ACL, Stroke, Multiple sclerosis, Dentistry, Pharmaceutical industry

"We created face mask born from the most successful therapies used to heal skin and grow collagen.

Key Points: 
  • "We created face mask born from the most successful therapies used to heal skin and grow collagen.
  • Springs Rejuvenation gained most of its notoriety though stem cell and exosome joint injections of professional athletes.
  • Springs Rejuvenation has been collecting data from IV stem cell and exosome therapy for many of the nations top medical conditions.
  • Located thought the US Springs Rejuvenation is the nations leading stem cell center with locations in Miami Florida, Atlanta Georgia, Austin Texas, and Los Angeles.

Springs Rejuvenation Inc. Provides Shareholder Update

Retrieved on: 
Thursday, March 24, 2022
Rejuvenation, Regenerative medicine, Perimeter Center, Stem cell, American Top Team, OTC Markets Group, Pain, Quality of life, LLC, Securities Exchange Act of 1934, Securities Act of 1933, GLOBE, Back pain, Drug Quality and Security Act, Athlete, Stem-cell therapy, Freedom, Patient, Partnership, Pharmaceutical industry

ATLANTA, GA, March 24, 2022 (GLOBE NEWSWIRE) -- via NewMediaWire -- Springs Rejuvenation Inc. (OTC Pink: SPRJ) is pleased to provide a shareholder update.

Key Points: 
  • ATLANTA, GA, March 24, 2022 (GLOBE NEWSWIRE) -- via NewMediaWire -- Springs Rejuvenation Inc. (OTC Pink: SPRJ) is pleased to provide a shareholder update.
  • Everett Dickson, Springs Rejuvenation CEO, stated, "We are delighted by the progress we have made since completing the merger between Avra, Inc (AVRN) and Springs Rejuvenation, LLC.
  • In October 2021 we completed the merger with Springs Rejuvenation, LLC, a Stem Cell and Anti-Aging Treatment Company
    In January 2022 we purchased two C-arm, high definition 3D imaging for direct visualization of the injection point.
  • At Springs Rejuvenation specializes in regenerative medicine and anti-aging research.

Global Nerve Repair and Regeneration Devices Market to Reach $11.8 Billion by 2026

Retrieved on: 
Wednesday, March 16, 2022
Siemens, Stem-cell therapy, Others, Regeneration, Neuromodulation, Neuroregeneration, Fluke Corporation, Forecasting, Players, PEG, COVID-19, LLC, Yokogawa Electric, Hospital, Research, Cancer, Population, Growth, Emerson Electric, Marketing, Intelligence, B cell, Parkinson's disease, Schneider Electric, ABB, Lists of diseases, Cerebral palsy, Alzheimer's disease, Prevalence, Mitsubishi Electric, Omron, SAN, Nerve, Osteoporosis, Ambulatory Surgery Center Association, Rockwell Automation, Littelfuse, CAGR, Nerve injury, Ageing, Awareness, Incidence, Industry, GIA, Pharmaceutical industry, Biomaterial

SAN FRANCISCO, March 16, 2022 /PRNewswire/ -- A new market study published by Global Industry Analysts Inc., (GIA) the premier market research company, today released its report titled "Nerve Repair and Regeneration Devices - Global Market Trajectory & Analytics" .

Key Points: 
  • SAN FRANCISCO, March 16, 2022 /PRNewswire/ -- A new market study published by Global Industry Analysts Inc., (GIA) the premier market research company, today released its report titled "Nerve Repair and Regeneration Devices - Global Market Trajectory & Analytics" .
  • Amid the COVID-19 crisis, the global market for Nerve Repair and Regeneration Devices estimated at US$7.8 Billion in the year 2022, is projected to reach a revised size of US$11.8 Billion by 2026, growing at a CAGR of 10% over the analysis period.
  • This segment currently accounts for a 13.8% share of the global Nerve Repair and Regeneration Devices market.
  • The U.S. Market is Estimated at $2.4 Billion in 2022, While China is Forecast to Reach $1.8 Billion by 2026
    The Nerve Repair and Regeneration Devices market in the U.S. is estimated at US$2.4 Billion in the year 2022.

Springs Rejuvenation Inc. Establishes Partnership with American Top Team Company

Retrieved on: 
Tuesday, March 15, 2022
Rejuvenation, Quality of life, Stem-cell therapy, GLOBE, Patient, Partnership, Pain, Stem cell, Regenerative medicine, MMA, UFC, Freedom, Injury, American Top Team, BJJ, Securities Exchange Act of 1934, Exercise, Drug Quality and Security Act, OTC, Securities Act of 1933, Athlete, Risk management

Atlanta, GA, March 15, 2022 (GLOBE NEWSWIRE) -- via NewMediaWire -- Springs Rejuvenation Inc. (OTC: SPRJ), announced a partnership with American Top Team, a leading gym for MMA, BJJ and Fitness Training, by providing stem cell therapies and treatments to their members and competitive athletes.

Key Points: 
  • Atlanta, GA, March 15, 2022 (GLOBE NEWSWIRE) -- via NewMediaWire -- Springs Rejuvenation Inc. (OTC: SPRJ), announced a partnership with American Top Team, a leading gym for MMA, BJJ and Fitness Training, by providing stem cell therapies and treatments to their members and competitive athletes.
  • Dr Charles Pereyra, Springs Rejuvenation Founder and Chief Operating Officer, stated, I am excited for the opportunity to partner with American Top Team which is one of the worlds premier facilities for training elite combat athletes, including both UFC and Bellator Champions.
  • I consider it an honor and responsibility to work with the athletes at American Top Talent.
  • At Springs Rejuvenation specializes in regenerative medicine and anti-aging research.

Springs Rejuvenation Inc. Announces Name Change and New Trading Symbol, and the Opening of a New Location in South Florida

Retrieved on: 
Wednesday, March 9, 2022
Industry, Drug Quality and Security Act, Medicine, Drug, Securities Act of 1933, Research, I-95, PRP, Stem-cell therapy, Quality of life, Rejuvenation, Health, Pain, OTC Markets Group, Securities Exchange Act of 1934, Stem cell, Athlete, GLOBE, Patient, Regenerative medicine, Prolotherapy, Technology, Freedom

Everett Dickson, Springs Rejuvenation CEO, stated, We are excited to serve the health and welfare needs of people in the metro Fort Lauderdale area.

Key Points: 
  • Everett Dickson, Springs Rejuvenation CEO, stated, We are excited to serve the health and welfare needs of people in the metro Fort Lauderdale area.
  • We are equally excited that we can move forward as a public company with our new name and trading symbol which reflects on our business.
  • Our purpose at Springs Rejuvenation is to assist you in feeling your best with full body health and well-being.
  • Our Medical Director & Founder is Dr. Charles A. Pereyra and the founder of Springs Rejuvenation Stem Cell Therapy in Atlanta, GA (since 2018).

Global Vaccines, Gene Therapy, and Stem Cell Therapy Innovations Report 2021 - ResearchAndMarkets.com

Retrieved on: 
Monday, August 9, 2021
Health, Genetics, Stem Cells, Pharmaceutical, Medical Supplies, Stem-cell therapy, Cancer, Ministry of Education (Malaysia), Solution, COVID-19, Cosmeceutical, Skin, Immunotherapy, Retina, Vaccine

The "Growth Opportunities in Vaccines, Gene Therapy, and Stem Cell Therapy" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Growth Opportunities in Vaccines, Gene Therapy, and Stem Cell Therapy" report has been added to ResearchAndMarkets.com's offering.
  • This report discusses multiple developments in vaccine technologies, both prophylactic and therapeutic.
  • Most of the innovations highlighted are around influenza, COVID-19, and cancer vaccines.
  • Further, innovations in emerging technologies such as gene therapy for retinal diseases, immunotherapy for cancers, developments in nutraceuticals for cardiovascular protection and cosmeceuticals for skin and hair care and protein-based sweeteners are also profiled in this TOE.

FDA Gives Green Light for Multiple Sclerosis Stem Cell Trial

Retrieved on: 
Tuesday, July 27, 2021
Research, FDA, Clinical trials, Philanthropy, Stem cells, Biotechnology, General Health, Health, Foundation, Science, Branches of biology, Biology, Life sciences, Stem cells, Biotechnology, Cell biology, Cloning, Developmental biology, Mesenchymal stem cell, Adult stem cell, Stem-cell therapy, Shimon Slavin

Non-profit research organization Hope Biosciences Stem Cell Research Foundation (HBSCRF) has received FDA authorization for a randomized, double-blind, single center, Phase II clinical trial to assess the efficacy of multiple intravenous infusions of autologous adipose-derived mesenchymal stem cells in improving symptoms and quality of life in patients with mild-to-moderate multiple sclerosis (MS).

Key Points: 
  • Non-profit research organization Hope Biosciences Stem Cell Research Foundation (HBSCRF) has received FDA authorization for a randomized, double-blind, single center, Phase II clinical trial to assess the efficacy of multiple intravenous infusions of autologous adipose-derived mesenchymal stem cells in improving symptoms and quality of life in patients with mild-to-moderate multiple sclerosis (MS).
  • A single infusion in the treatment group consists of 200 million stem cells, or approximately 1.2 billion stem cells per patient over the course of study.
  • HBSCRF remains the only organization globally to administer pure, fresh mesenchymal stem cells, an adult stem cell harvested from fat, in such high quantities over repeat treatments.
  • Clinical trial authorizations encompass COVID-19 prevention and treatment , traumatic brain injury , Parkinsons disease , and multiple sclerosis.

InGeneron Reports First-In-Human Microscopic Evidence of Adult Tendon Regeneration Following Autologous Stem Cell Treatment

Retrieved on: 
Monday, July 26, 2021
Research, Surgery, FDA, Genetics, Clinical trials, Stem cells, Biotechnology, Physical therapy, Health, Science, Branches of biology, Biology, Life sciences, Healing, Developmental biology, Biotechnology, Cloning, Stem cell, Tendon, Regeneration, Scar, Stem-cell therapy, the Transpose® RT System and FDA approved clinical trials, InGeneron, THE TRANSPOSE® RT SYSTEM AND FDA APPROVED CLINICAL TRIALS, INGENERON

This newly-released research paper, titled First Immunohistochemical Evidence of Human Tendon Repair Following Stem Cell Injection: A Case Report and Review of Literature , was published in the World Journal of Stem Cells on July 23, 2021 (DOI: https://dx.doi.org/10.4252/wjsc.v13.i7.944 ).

Key Points: 
  • This newly-released research paper, titled First Immunohistochemical Evidence of Human Tendon Repair Following Stem Cell Injection: A Case Report and Review of Literature , was published in the World Journal of Stem Cells on July 23, 2021 (DOI: https://dx.doi.org/10.4252/wjsc.v13.i7.944 ).
  • The analysis strongly indicates regenerative healing of the tendon, resulting from transformation of UA-ADRCs into new tendon tissue.
  • Importantly, the investigated tendon showed evidence of histological regeneration without scar formation, a finding indicating significant advantages over existing treatments options.
  • The microscopic images of the tendon treated with stem cells clearly demonstrate that a different type of healing had taken place.

Poseida Therapeutics Appoints Cynthia Collins to Board of Directors

Retrieved on: 
Monday, July 26, 2021
Life sciences, Biotechnology, Articles, Pharmacy, Biopharmaceutical, Pharmaceutical industry, United Therapeutics, Draft:Leaps by Bayer

SAN DIEGO, July 26, 2021 /PRNewswire/ --Poseida Therapeutics, Inc. (Nadsaq: PSTX), a clinical-stage biopharmaceutical company utilizing proprietary genetic engineering platform technologies to create cell and gene therapeutics with the capacity to cure, today announced the appointment of biotechnology industry veteran Cynthia Collins to its Board of Directors, effective July 23, 2021.

Key Points: 
  • SAN DIEGO, July 26, 2021 /PRNewswire/ --Poseida Therapeutics, Inc. (Nadsaq: PSTX), a clinical-stage biopharmaceutical company utilizing proprietary genetic engineering platform technologies to create cell and gene therapeutics with the capacity to cure, today announced the appointment of biotechnology industry veteran Cynthia Collins to its Board of Directors, effective July 23, 2021.
  • "We are excited to welcome Cindy to Poseida's Board of Directors," said Eric Ostertag, M.D., Ph.D., Chief Executive Officer of Poseida Therapeutics.
  • "As a recognized leader in cell and gene therapies and in growing innovative companies, she brings more than four decades of experience to our Board.
  • Poseida Therapeutics is a clinical-stage biopharmaceutical company dedicated to utilizing our proprietary genetic engineering platform technologies to create next generation cell and gene therapeutics with the capacity to cure.

Worldwide Stem Cell Banking Industry to 2026 - Featuring CBR Systems, Cordlife and Lifecell Among Others - ResearchAndMarkets.com

Retrieved on: 
Thursday, July 15, 2021
Health, Stem cells, Articles, Branches of biology, Biology, Stem cells, Biotechnology, Cell biology, Cloning, Stem-cell therapy, Bank, Science, technology, engineering, and mathematics

The "Stem Cell Banking Market: Global Industry Trends, Share, Size, Growth, Opportunity and Forecast 2021-2026" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Stem Cell Banking Market: Global Industry Trends, Share, Size, Growth, Opportunity and Forecast 2021-2026" report has been added to ResearchAndMarkets.com's offering.
  • The global stem cell banking market exhibited strong growth during 2015-2020.
  • Looking forward, the publisher expects the global stem cell banking market to reach a value of US$ 21.5 Billion by 2026.
  • Stem cell banking is one of the most promising as well as the fastest growing segment of the next-generation stem cell therapy.